R01 CA164024/CA/NCI NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
2015	1
2017	2
2018	4
2019	1
2020	1
2021	5
2022	3
2023	4
2024	0

1

Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712.

Tarlock K, Liu X, Minard CG, Isikwei EA, Reid JM, Horton TM, Fox E, Weigel BJ, Cooper T. Tarlock K, et al. Pediatr Blood Cancer. 2023 Dec;70(12):e30672. doi: 10.1002/pbc.30672. Epub 2023 Sep 14. Pediatr Blood Cancer. 2023. PMID: 37710306 Clinical Trial.

2

Valosin-containing protein (VCP/p97) is prognostically unfavorable in pediatric AML, and negatively correlates with unfolded protein response proteins IRE1 and GRP78: A report from the Children's Oncology Group.

Hoff FW, Qiu Y, Brown BD, Gerbing RB, Leonti AR, Ries RE, Gamis AS, Aplenc R, Kolb EA, Alonzo TA, Meshinchi S, Jenkins GN, Horton TM, Kornblau SM. Hoff FW, et al. Proteomics Clin Appl. 2023 Nov;17(6):e2200109. doi: 10.1002/prca.202200109. Epub 2023 Jun 7. Proteomics Clin Appl. 2023. PMID: 37287368

3

Reverse Phase Protein Array Profiling Identifies Recurrent Protein Expression Patterns of DNA Damage-Related Proteins across Acute and Chronic Leukemia: Samples from Adults and the Children's Oncology Group.

Hoff FW, Griffen TL, Brown BD, Horton TM, Burger J, Wierda W, Hubner SE, Qiu Y, Kornblau SM. Hoff FW, et al. Int J Mol Sci. 2023 Mar 13;24(6):5460. doi: 10.3390/ijms24065460. Int J Mol Sci. 2023. PMID: 36982537 Free PMC article.

4

IL-10 and TNFα are associated with decreased survival in low-risk pediatric acute myeloid leukemia; a children's oncology group report.

Stevens AM, Horton TM, Glasser CL, Gerbing RB, Aplenc R, Alonzo TA, Redell MS. Stevens AM, et al. Pediatr Hematol Oncol. 2023 Mar;40(2):147-158. doi: 10.1080/08880018.2022.2089790. Epub 2022 Jul 15. Pediatr Hematol Oncol. 2023. PMID: 35838057 Free PMC article.

5

Clinical relevance of proteomic profiling in de novo pediatric acute myeloid leukemia: a Children's Oncology Group study.

Hoff FW, Van Dijk AD, Qiu Y, Hu CW, Ries RE, Ligeralde A, Jenkins GN, Gerbing RB, Gamis AS, Aplenc R, Kolb EA, Alonzo TA, Meshinchi S, Qutub AA, De Bont ESJM, Horton TM, Kornblau SM. Hoff FW, et al. Haematologica. 2022 Oct 1;107(10):2329-2343. doi: 10.3324/haematol.2021.279672. Haematologica. 2022. PMID: 35021602 Free PMC article.

6

Reverse phase protein arrays in acute leukemia: investigative and methodological challenges.

Hoff FW, Horton TM, Kornblau SM. Hoff FW, et al. Expert Rev Proteomics. 2021 Dec;18(12):1087-1097. doi: 10.1080/14789450.2021.2020655. Epub 2021 Dec 29. Expert Rev Proteomics. 2021. PMID: 34965151 Free PMC article. Review.

7

Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF-κB subunit RelA.

van Dijk AD, Hoff FW, Qiu Y, Gerbing RB, Gamis AS, Aplenc R, Kolb EA, Alonzo TA, Meshinchi S, Jenkins GN, de Bont ESJM, Kornblau SM, Horton TM. van Dijk AD, et al. Proteomics Clin Appl. 2022 Mar;16(2):e2100072. doi: 10.1002/prca.202100072. Epub 2021 Nov 17. Proteomics Clin Appl. 2022. PMID: 34719869 Free PMC article. Clinical Trial.

8

Defining the transcriptional control of pediatric AML highlights RARA as a superenhancer-regulated druggable dependency.

Perez MW, Sias-Garcia O, Daramola A, Wei H, Terrell M, Rashid R, Park WD, Duong K, Horton TM, Li F, Cherayil N, Koren JV, Gant VU, Junco JJ, Curry CV, Stevens AM, Lin CY, Yi JS. Perez MW, et al. Blood Adv. 2021 Dec 14;5(23):4864-4876. doi: 10.1182/bloodadvances.2020003737. Blood Adv. 2021. PMID: 34543389 Free PMC article.

9

The effects of sample handling on proteomics assessed by reverse phase protein arrays (RPPA): Functional proteomic profiling in leukemia.

Horton TM, Hoff FW, van Dijk A, Jenkins GN, Morrison D, Bhatla T, Hogan L, Romanos-Sirakis E, Meyer J, Carroll WL, Qiu Y, Wang T, Mo Q, Kornblau SM. Horton TM, et al. J Proteomics. 2021 Feb 20;233:104046. doi: 10.1016/j.jprot.2020.104046. Epub 2020 Nov 16. J Proteomics. 2021. PMID: 33212251 Free PMC article.

10

Heat shock factor 1 (HSF1-pSer326) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG report.

Hoff FW, van Dijk AD, Qiu Y, Ruvolo PP, Gerbing RB, Leonti AR, Jenkins GN, Gamis AS, Aplenc R, Kolb EA, Alonzo TA, Meshinchi S, de Bont ESJM, Bruggeman SWM, Kornblau SM, Horton TM. Hoff FW, et al. Blood. 2021 Feb 25;137(8):1050-1060. doi: 10.1182/blood.2020005208. Blood. 2021. PMID: 32959058 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

17 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year